Participated · Series A · Dec 2025

Excellergy focuses on creating a new class of allergic Effector Cell Response Inhibitors (ECRIs) designed to block the cellular mechanisms that drive allergic reactions. The company, which publicly launched alongside its financing, is building a pipeline of first-in-class therapies aimed at transforming allergy treatment. Proceeds from its initial funding will be used to advance its lead ECRI candidates into first-in-human clinical studies. Management has not yet disclosed product timelines or commercial metrics, but the substantial Series A raise underscores strong investor confidence in the science. Backers highlight the potential for Excellergy’s platform to address a broad range of allergic diseases where current options are limited. The company positions itself to move rapidly through early clinical development thanks to the sizable capital infusion. No revenue or user metrics have been released to date.

Participated · Series A · Oct 2024

Kivu Bioscience develops next-generation antibody-drug conjugates (ADCs) using a proprietary Synaffix site-specific linker-payload platform and GlycoConnect™ technology. The platform couples linkers to asparagine-297 to produce highly homogeneous, stable ADCs that the company says reduce off-target toxicity and widen the therapeutic window. Kivu's assets are in late-stage preclinical studies, including a Topo1i-based ADC pipeline targeting solid tumors. The company plans to advance its first two lead candidates into Phase 1 trials in 2025 and to move multiple oncology programs into the clinic. Kivu is led by an experienced team headed by Mohit Trikha, Ph.D., and is headquartered in San Francisco, CA. The company closed a $92 million Series A to support clinical development across its ADC programs.

Participated · Series B · Mar 2024

Engrail Therapeutics is a clinical-stage pharmaceutical company focused on precision neuroscience and the development of transformational therapies for patients with neuropsychiatric and neurodevelopmental diseases. Its pipeline targets conditions with high unmet need, including anxiety disorders, depression, posttraumatic stress disorder, and rare neurodegenerative diseases. The company is advancing multiple programs through clinical development and is conducting an ongoing ENX-102 Phase 2 study in generalized anxiety disorder. Management states the Series B funding will propel advancement of the pipeline through multiple clinical stages and enable delivery of value-creating milestones. Engrail was incubated with support from Pivotal Life Sciences and aims to become a leader in neuroscience. Engrail Therapeutics is a neuroscience company that acquires, develops and commercializes patient-centric therapies, with lead compounds that are subtype-selective GABA-A modulators. The company is advancing a diverse pipeline, including lead assets ENX-101 and ENX-102 as well as internal preclinical programs. Earlier this year Engrail initiated a Phase 1b study for ENX-101 and a Phase 1a study for ENX-102. Engrail will use proceeds from its recent financing to accelerate clinical development and build out clinical development capabilities. The company operates via a flexible transaction model—licensing, co-development and company acquisitions—to acquire assets with validated mechanisms for nervous system diseases. Engrail was founded in 2019 and is supported by a long-term capital commitment from Nan Fung Life Sciences. Engrail Therapeutics focuses on acquiring, developing and commercializing therapies for diseases of the nervous system. Its lead pipeline asset is ENX-101, a subtype‑selective GABAA modulator that the company plans to advance clinically. Engrail applies a "science‑first" approach to identify compounds with validated mechanisms and a lower‑risk path to market. The company uses a flexible transaction model — including licensing, co‑development and company acquisitions — to build a diversified portfolio. Engrail closed a $32 million Series A to support ENX-101’s clinical development and is backed by a long‑term capital commitment from Nan Fung Life Sciences. Founded in 2019 and based in San Diego, Engrail emphasizes clinical strategy, regulatory planning, intellectual property and commercial positioning.

Led · Series B · Mar 2023

Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class bifunctional antibodies that combine tumor-targeting with tumor microenvironment modulation. Its lead candidate, BCA101, is a dual-action EGFR/TGF-β inhibitor in an open-label Phase 1/1b dose expansion being evaluated as monotherapy and in combination with pembrolizumab for frontline HPV-negative R/M HNSCC, advanced SqNSCLC, and cutaneous squamous cell carcinoma. Bicara presented positive interim clinical data at ASCO 2023 and ESMO 2023 demonstrating clinically meaningful anti-tumor activity and a tolerable safety profile in frontline HPV-negative R/M HNSCC. Additional data updates from the ongoing Phase 1/1b study, including in advanced SqNSCLC, are anticipated in 2024. Proceeds from the Series C financing will support continued advancement of BCA101. With the completion of the Series C, Bicara has raised $273 million in 2023. Bicara Therapeutics develops first-in-class bifunctional antibodies that combine targeted therapy precision with tumor modulators to deliver immunomodulatory payloads directly to the tumor microenvironment. Its lead asset, BCA101, is an EGFR / TGF-β-trap bifunctional antibody intended to inhibit EGFR and disable TGF-β at the tumor site to improve anti-tumor responses and the therapeutic window. BCA101 is currently enrolling patients in a Phase 1/1b study and the company has reported promising efficacy and safety data, with plans to present additional data at a medical conference in 2023. Bicara is also advancing IND-enabling studies for a second program, BCA356. The company says it intends to execute future clinical studies of BCA101 in the U.S. and Europe. Bicara is based in Cambridge, Mass.

Participated · Series A · Mar 2023

Cargo Therapeutics is a San Mateo, CA–based biotechnology company advancing next-generation CAR T-cell therapies for cancer. Launched in 2021 by Samsara BioCapital in collaboration with CAR T pioneers Crystal Mackall, MD, and Robbie Majzner, MD, and cancer advocate Nancy Goodman, the company is led by CEO Gina Chapman. Cargo leverages proprietary platform technologies to engineer and develop next-generation, best-in-class CARs that incorporate complex therapeutic cargo. Its platform aims to achieve durable responses that are curative for more cancer patients. The company intends to use proceeds to advance its autologous CD22 CAR T candidate, CRG-022, through a pivotal multicenter Phase 2 trial in patients with LBCL whose disease has relapsed or is refractory to CD19 CAR T therapy. It will also use funds to advance its proprietary platform technologies and discovery-stage programs to deliver better outcomes for patients with high unmet need.